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scription if it had been started in secondary or tertiary care. 
 Conclusions: Barriers to implementing preventive therapy 
within routine clinical practice are common and could be ad-
dressed by engaging all stakeholders during the develop-
ment of policy documents.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Background 
 Breast cancer is the most commonly diagnosed cancer 
in developed countries, and incidence is increasing world-
wide  [1] . Treatment advances have improved survival  [2, 
3] , but primary prevention can play a role in reducing 
disease burden. Preventive therapy using Selective Oes-
trogen-Receptor Modulators (SERMs) such as tamoxifen 
and raloxifene can reduce incidence of breast cancer by 
30% or more among higher-risk women  [4] . SERMs also 
increase the risk of a thromboembolic event, endometrial 
cancer, and menopausal side effects. A meta-analysis re-
ported that 16% of women accepted the offer of preven-
tive therapy  [5] , but most were US studies and initiation 
in the UK may be lower  [6] . Uptake to preventive therapy 
trials is higher than initiation rates observed in clinical 
settings  [5] .
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 Abstract 
 Aims: The use of tamoxifen and raloxifene as preventive 
therapy for women at increased risk of breast cancer was ap-
proved by the National Institute for Health and Care Excel-
lence (NICE) in 2013. We undertook a qualitative investiga-
tion to investigate the factors affecting the implementation 
of preventive therapy within the UK.  Methods: We recruited 
general practitioners (GPs) (n = 10) and clinicians working in 
family history or clinical genetics settings (FHCG clinicians) 
(n = 15) to participate in semi-structured interviews. Data 
were coded thematically within the Consolidated Frame-
work for Implementation Research.  Results: FHCG clinicians 
focussed on the perceived lack of benefit of preventive ther-
apy and difficulties interpreting the NICE guidelines. FHCG 
clinicians felt poorly informed about preventive therapy, 
and this discouraged patient discussions on the topic. GPs 
were unfamiliar with the concept of preventive therapy, and 
were not aware that they may be asked to prescribe it for 
high-risk women. GPs were reluctant to initiate therapy be-
cause it is not licensed, but were willing to continue a pre-
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 In 2013, the UK National Institute for Health and Care 
Excellence (NICE) approved the use of tamoxifen and ral-
oxifene for women at increased risk due to their family 
history  [7] . Several UK genetics and family history cen-
tres were involved in the IBIS-I trial that provided data to 
support this decision  [8] . However, patient enrolment 
was between 1992 and 2001, meaning many clinicians are 
unfamiliar with tamoxifen and do not have experience 
discussing its use with patients. Furthermore, not all UK 
centres were involved in the IBIS-I trial, and the barriers 
to implementing the NICE guidelines experienced by 
these clinicians are largely unknown.
 A national survey in the US reported that 27% of phy-
sicians had prescribed tamoxifen for breast cancer pre-
vention in the last year  [9] . However, an Australian study 
suggested opportunities to discuss preventive therapy 
may be being missed, with <60% of relevant consultations 
including a discussion about chemoprevention  [10] . 
There have been few attempts to understand clinician at-
titudes. A focus group study in Australia in 2009 reported 
a degree of confusion over the eligibility of specific pa-
tient groups, with some clinicians expressing greater con-
fidence in discussing preventive therapy with carriers of 
deleterious BRCA1 and BRCA2 mutations, despite poor 
evidence in this group  [11] . Clinicians recognised their 
limitations in knowledge, and this affected their willing-
ness to discuss it with patients. The status of tamoxifen as 
an unlicensed medication was also a barrier to imple-
menting preventive therapy. Although UK general prac-
titioners (GPs) prescribe ‘off-label’ medications in other 
contexts, their willingness to offer tamoxifen and raloxi-
fene for the primary prevention of breast cancer is not 
known  [12–14] .
 Only a small proportion of medical innovations and 
technologies result in changes to routine clinical practice 
 [15] , and there is wide variation in the rates of implemen-
tation between clinicians and healthcare organisations 
 [16] . Barriers to implementation may exist at multiple 
levels, including at the patient, provider, organisation and 
policy stages  [17] . Implementation science models have 
been developed to explain why medical innovations are 
not introduced into practice by incorporating factors 
across these levels  [18] . These models could explain why 
preventive therapy is poorly accepted by both clinicians 
and patients in routine clinical practice.
 The Consolidated Framework for Implementation Re-
search (CFIR) is a meta-theoretical model comprised of 
common constructs from a range of implementation sci-
ence theories  [18] . The CFIR outlines five domains that 
affect the likelihood of a clinical guideline or medical in-
novation being incorporated into routine care, each of 
which is composed of sub-themes ( fig. 1 ;  table 1 ). Quali-
tative enquiry with key stakeholders is needed to identify 
which of these domains is important in the context of 
implementing preventive therapy. The CFIR is supported 
by findings from a meta-review of 12 systematic reviews, 
which found evidence for its major themes in the context 
of implementing clinical guidelines  [19] . The model has 
also received support from a study investigating factors 
affecting the prescription of new medications among 
rheumatologists  [20] . Identifying the most serious chal-
lenges to implementation using models such as the CFIR 
can help to inform future healthcare policy.
 Ensuring preventive therapy is adequately prescribed 
in the NHS is a priority of the Independent Cancer Task-
force  [21] . Incorporating the perspective of key stake-
Implementation
Intervention
characteristics Inner setting Outer setting
Implementation
process
Individuals
involved
Evidence
strength
Relative
advantage
Trialability
Climate for
implementing
new
technology
External
policies
Knowledge
and attitude
Self-efficacy
Planning
Engaging
others in plans
Reflection
and evaluation Fig. 1. Overview of CFIR as applied to pre-
ventive therapy. See  table 1 for detailed de-
scriptions of themes and sub-themes. 
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holders can identify the precise levels and contexts in 
which barriers occur, allowing quality improvement 
measures to be put in place. We used semi-structured
interviews to investigate the barriers to implementing 
breast cancer preventive therapy within a UK clinical set-
ting among GPs and clinicians caring for women with 
increased risk of familial breast cancer.
 Methods 
 Management of People at Risk of Breast Cancer 
 The management of women at increased risk of breast cancer in 
the UK National Health Service involves primary, secondary and 
tertiary care services and follows NICE guidance  [7] . The most com-
mon management pathway is for patients to present to their GP be-
cause of concerns about their risk of breast cancer. Women meeting 
NICE referral criteria are seen in specialist family history clinics 
(FHCs), clinical genetics services or breast clinics, depending on lo-
cal protocol. Moderate-risk women (17–30% lifetime risk) and high-
risk women ( ≥ 30% lifetime risk) are offered annual mammography, 
and some clinical groups can access MRI surveillance  [7] . There is 
no formal established pathway for the prescription of preventive 
therapy. For newly referred patients, preventive therapy is discussed 
during the initial appointment within secondary or tertiary care. For 
patients already registered with FHCs and genetics services, preven-
tive therapy is discussed during follow-up appointments.
 Sample of Clinicians 
 An overview of our research programme was presented at a na-
tional clinical genetics research meeting, a national breast physician 
meeting and two local multidisciplinary team meetings. A request 
was made for clinicians to take part in a 30- to 40-min interview on 
the topic of breast cancer preventive therapy. This approach was 
taken to purposively recruit clinicians with different levels of experi-
ence and with backgrounds in different disciplines. Inclusion crite-
ria were having a patient caseload and working in a clinic where 
breast cancer preventive therapy could be discussed with patients, 
even if it was not current protocol. Family history and clinical genet-
ics clinicians (herein referred to as FHCG clinicians) were either 
breast physicians or clinicians, family history nurses, nurse practi-
tioners, clinical geneticists, genetic counsellors or surgeons. Those 
recruited were from the South-East of England, the Midlands and 
Yorkshire. GPs were paid £50 to participate and were asked to con-
tact the lead investigator (S.G.S.) if they were interested in partici-
pating. Advertising for the study was sent through professional net-
works. GPs were eligible if they had a current patient caseload. 
 Procedure 
 Clinicians approaching the lead investigator were sent an in-
formation sheet and consent form. An interview was scheduled at 
a mutually convenient time and location. The majority of inter-
views (n = 19) were done by telephone. At the beginning of the 
interview, clinicians were asked structured questions about their 
clinical background and experience (see online suppl. appendix; 
see www.karger.com/doi/10.1159/000447552). This included in-
formation on their current patient caseload, the type of clinic they 
work in and their level of clinical experience. FHCG clinicians 
were asked for their typical appointment duration, patient volume 
per year and their personal and hospital’s experience in recruiting 
to preventive therapy trials. GPs were asked about their experience 
referring patients to secondary or tertiary care due to a familial risk 
of breast cancer.
 In the semi-structured interview, FHCG clinicians were asked 
about their attitudes towards preventive therapy, how it is imple-
 Table 1. Definitions of identified themes within the CFIR as 
applied to preventive therapy
Construct Definition
Intervention characteristics
Evidence strength Stakeholders’ perceptions of the quality and 
validity of evidence supporting 
chemoprevention
Relative 
advantage
Stakeholders’ perception of the advantage of 
implementing chemoprevention versus an 
alternative solution
Trialability The ability to test chemoprevention on a small 
scale in the organization
Complexity Perceived difficulty of implementing 
chemoprevention, reflected by disruptiveness 
and number of steps required
Costs Financial costs associated with implementing 
chemoprevention
Inner setting
Implementation 
climate
The capacity for change and extent to which 
use of chemoprevention will be rewarded, 
supported, and expected by the institution and 
colleagues
Outer setting
External policies External strategies to spread use of 
chemoprevention, including policy and 
regulations (e.g. NICE guidelines) 
Individual characteristics
Knowledge and 
attitudes
Individuals’ attitudes toward chemoprevention 
as well as familiarity with factual information 
about chemoprevention
Self-efficacy Individual belief in their own capabilities to 
execute courses of action to achieve 
chemoprevention goals
Implementation process
Planning The degree to which tasks for implementing 
chemoprevention are developed in advance, 
and the quality of that planning
Engaging others 
in plans
Attracting and involving appropriate 
individuals in the implementation of 
chemoprevention through various strategies 
Definitions adapted from the CFIR website: http://cfirguide.
org/constructs.html; only constructs identified in the interviews 
are included here. Issues associated with the implementation 
process were incorporated within other themes (e.g. external 
policies).
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mented within their clinic, their perception of the evidence, and the 
local processes for prescribing tamoxifen or raloxifene ( fig. 2 ). Dif-
ficulties implementing preventive therapy within everyday clinical 
practice were pursued with additional questioning. GPs were asked 
about their familiarity with the topic of preventive therapy, their ex-
perience and willingness to prescribe tamoxifen and raloxifene for 
primary prevention, local processes for prescribing new medications, 
and issues associated with prescribing ‘off-label’ medication ( fig. 2 ). 
After eliciting initial reactions to preventive therapy, the evidence for 
SERMs was described using data from the most up-to-date meta-
analysis  [4] . The topic guide was developed collaboratively within the 
research team (S.G.S., L.S., J.W.) and refined as the study progressed. 
The interviews were undertaken by a behavioural scientist with ex-
pertise in qualitative research methods (S.G.S.) between November, 
2014 and July, 2015. Ethical approval was obtained from the Queen 
Mary University of London Research Ethics Committee.
 Analysis 
 Interviews were digitally recorded and transcribed verbatim. 
Thematic analysis was used to identify patterns (described here as 
themes) within the interview data  [22] . Each transcript was read 
several times by two independent researchers (S.G.S. and S.F.M.) 
and coding began when they were familiar with the data. Descrip-
tive themes were produced inductively based on the data. Data 
from FHCG clinicians were initially analysed separately from the 
GPs in recognition of their different experience and understanding 
of preventive therapy. Following the independent generation of 
descriptive themes by two researchers (S.G.S. and S.F.M.), the pro-
cess of grouping the independent datasets into higher level ana-
lytical themes was initiated. This process was informed by the ex-
isting CFIR model ( table  1 )  [18] , but disconfirming data were 
sought throughout  [23] . Interview data from both FHCG clini-
cians and GPs were then combined to identify similar barriers to 
the implementation of preventive therapy. The quotes presented 
here are the richest examples of the finalised analytical themes. All 
analyses were performed in a Microsoft Office Excel database.
 Results 
 Sample 
 Fifteen FHCG clinicians were recruited ( table  2 ). 
Thirteen were women (87%) and were generally highly 
experienced, with 80% having at least 6 years’ experience. 
The majority were recruited from clinical genetics ser-
vices (40%) or family history clinics (47%), and there was 
a wide range in patient volume per year. Nine clinicians 
(60%) had a clinical caseload involving both moderate 
and high-risk groups, and 6 (40%) saw high-risk women 
only. Four (27%) of the FHCG clinicians had personally 
recruited for breast cancer-preventive therapy trials, al-
though 53% worked in centres that were involved in tri-
al recruitment. Two FHCG clinicians worked in centres 
that did not discuss preventive therapy with eligible pa-
tients.
 Ten GPs were included ( table 3 ). Most were women 
(90%) and worked in larger practices (>12,000 registered 
patients) (60%). The GPs had a range of experience lev-
els, and most (80%) had experience of referring a patient 
to secondary or tertiary care because of her familial risk 
of breast cancer. Four of the GPs were familiar with the 
NICE guidelines for preventive therapy, and 2 were 
working in practices where preventive therapy had been 
discussed with a patient. However, no GP within this 
study had personally been asked to prescribe preventive 
therapy.
Genetics and family history interview GP interview
⚫ Thank you and introduction to the project ⚫ Thank you and introduction to the project
⚫ Structured questions (table 2) ⚫ Structured questions (table 3)
⚫ In your own words, please tell me what you think about breast cancer 
chemoprevention
⚫ In your own words, please tell me what you know about breast 
cancer chemoprevention
– Is chemoprevention routinely offered in your current practice – Were you familiar with the NICE guidelines before today?
– Is there a standard protocol for offering chemoprevention? – Have you ever been asked to prescribe chemoprevention?
– What do you think of the evidence behind chemoprevention? – If a woman was interested, what would be the next steps?
– If a woman was interested, what would be the next steps? – What are your thoughts about tamoxifen and raloxifene being 
‘off-label’
⚫ Brief description of preventive therapy evidencea
 a Described evidence was from Cuzick et al. [4]. GPs were told that there was a ~40% reduction in breast cancer incidence among women taking 
preventive therapy for 5 years, which was accompanied by an increase in thromboembolic events, endometrial cancer and vasomotor symptoms. 
Twenty-two women need to take tamoxifen for 5 years to prevent one breast cancer case. There is no recorded mortality benefit among users.
 Fig. 2. Overview of interview schedule for FHCG clinicians and GPs. 
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 Summary of Qualitative Data 
 FHCG clinicians referred to all five domains of the 
CFIR, although the majority of discussion was focussed 
on the intervention characteristics (e.g. evidence and rel-
ative benefit) and the outer setting (e.g. NICE guidelines). 
Several quotes and topics covered multiple themes within 
the CFIR framework. As a result, no quotes were included 
for the ‘process’ theme. While processes such as planning 
and engaging were considered to be an important aspect 
of implementing preventive therapy, these issues were 
driven by factors within other themes (e.g. external poli-
cies). GPs also highlighted problems with external poli-
cies such as NICE guidelines, as well as concerns regard-
ing their own lack of awareness.
 Intervention Characteristics 
 Evidence Strength 
 The perceived benefits of preventive therapy varied. 
The recent release of trial data demonstrating a lack of ef-
fect on mortality reduction among women taking tamox-
ifen  [8] affected clinicians’ enthusiasm and led to the per-
ception that the absolute benefit for women was small: 
 ‘I wouldn’t be convinced about that [evidence for preventive 
therapy]. I don’t think there’s enough information to make a full 
decision, and the lack of long-term data is critical, really.’ (J.N., GP, 
male)
 Some FHCG clinicians and GPs were more positive 
and framed the decision to offer preventive therapy in 
terms of overall disease burden, rather than focussing on 
mortality outcomes:  
 ‘…even if you don’t reduce mortality, you can reduce [the] bur-
den of disease which is associated with a significant morbidity, 
anxiety of having diagnosed with cancer, and treatment costs and 
toxicities...If you can bring that entire burden down by 30%, then 
I think that is a sufficiently attractive proposition.’ (R.P., FHCG 
clinician, male)
 Some FHCG clinicians voiced enthusiasm for preven-
tive therapy with particular clinical groups. However, this 
was not always consistent because of confusion regarding 
which risk group it should be offered to. The perception 
among some FHCG clinicians was that preventive thera-
py trials mainly recruited moderate-risk women, and 
therefore the evidence was most relevant for them: 
 ‘I deal mainly with high-risk women, it’s not something that I 
was entirely comfortable with in the beginning because a lot of the 
studies are done in moderate-risk women who I don’t see that 
many of. So I find it quite difficult to have those kind of conversa-
tions…’ (T.D., FHCG clinician, female)
 However, other FHCG clinicians felt that the moder-
ate-risk group were not at a sufficiently high level of risk 
 Table 2. Characteristics of clinicians working in genetics and 
family history setting
Gender
Male 2 (13)
Female 13 (87)
Patient group
Moderate or high risk 9 (60)
High risk only 6 (40)
Clinic type
Clinical genetics service 6 (40)
Family history clinic 7 (47)
Breast clinic 2 (13)
Years since qualified
0 – 5 3 (20)
6 – 10 6 (40)
>10 6 (40)
Appointment times
≤15 min 3 (20)
15 – 30 min 4 (27)
31 – 45 min 6 (40)
45 min+ 1 (7)
Patient volume per year (clinic level)
≤100 5 (33)
101 – 500 5 (33)
500+ 5 (33)
Personal participation in IBIS trials
Yes 4 (27)
No 11 (73)
Centre participation in IBIS trials
Yes 8 (53)
No 7 (47)
Data are presented as n (%). Numbers may not compute to 15 
as one clinician did not have a dedicated clinic for seeing high-risk 
patients.
 Table 3. Characteristics of GPs
Gender
Male 1
Female 9
Years since qualified
0 – 10 3
11 – 20 6
20+ 1
Number of registered patients at current practice
≤12,000 3
>12,000 6
Experience of referring high-risk women 
Yes 8
No 2
One GP was a locum and therefore could not respond to the 
item regarding practice size.
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to warrant potential side effects, and therefore adopted a 
local policy to only discuss preventive therapy with high-
risk women: 
 ‘It was felt for the…moderate-risk group, the risk/benefit risk 
ratio wasn’t clear. You know, the side effect profile compared to 
the benefit that they would potentially get from chemoprevention, 
we didn’t feel was sufficient to offer them chemoprevention.’ 
(S.M., FHCG clinician, female)
 Relative Advantage 
 Several factors led FHCG clinicians to believe the rela-
tive advantage of offering preventive therapy was mini-
mal. The side effects experienced by healthy women using 
tamoxifen led clinicians to report they avoided conversa-
tions with some patients to prevent unnecessarily dis-
turbing their general physical and mental health: 
 ‘If someone is perfectly happy with their level of risk, their lev-
el of surveillance, and it’s all ticking over nicely, they’re breast 
aware, it’s not impacting on their life too much, I personally, may-
be subjectively, maybe subconsciously don’t really want to mess 
that up.’ (L.O., FHCG clinician, female)
 The ‘window of opportunity’ during which the advan-
tages of preventive therapy outweighed the harms was 
considered to be small. Some women at high risk of breast 
cancer are eligible for surgical intervention regardless of 
age, but preventive therapy is only available from the age 
of 35 years. Tamoxifen and raloxifene are also not avail-
able to women planning pregnancy or those taking the 
contraceptive pill. As a result, FHCG clinicians ques-
tioned the advantages of preventive therapy for large pro-
portions of this population: 
 ‘Yes, they recommend salpingo-oophorectomy from the age of 
40, so actually women having children in their 30s, then they get 
to 40 and then have an oophorectomy and then get put on HRT. 
There isn’t really, for the [BRCA 1 and BRCA 2] carriers, a big op-
portunity to take on tamoxifen.’ (S.M., FHCG clinician, female)
 Despite recognising the increase in morbidity associ-
ated with risk-reducing mastectomy, surgical interven-
tion was considered a more obvious choice for patients: 
 ‘So for example [risk-reducing mastectomy] does add life 
years…so you know, obviously that’s a very much harsher choice, 
but it’s so much better and clearer cut in what it offers.’ (C.S., 
FHCG clinician, female)
 There were also a number of examples of the ‘status 
quo’ effect, a phenomenon that occurs when two options 
are perceived to be comparable, but the most contempo-
rary option is neglected in favour of existing practice. Sev-
eral FHCG clinicians recognised the limitations associ-
ated with mammography, but still felt screening should 
be prioritised ahead of discussions about prevention: 
 ‘There’s…no really good data to say that mammography in 
women aged 40–50 is really going to improve survival from breast 
cancer. [But]…it’s been around for so long, and it’s generally an 
accepted recommendation.’ (S.M., FHCG clinician, female)
 Several FHCG clinicians felt that the relative advan-
tage of tamoxifen was small, and instead were anticipat-
ing that alternative agents with less pronounced side ef-
fect profiles would be more acceptable: 
 ‘…Although they [aromatase inhibitors, AIs] have their own 
side effects I suspect that a lot of these younger women will look at 
that profile in a less frightened way and I anticipate…that NICE 
will adopt AIs as well…and I think if they do, a lot more women 
may be interested.’ (R.I., FHCG clinician, female)
 Trialability 
 Only one FHCG clinician discussed the option of tak-
ing tamoxifen for a short trial period. They also failed to 
mention the option of trying tamoxifen and switching to 
raloxifene, despite a generally more favourable side effect 
profile  [24] . GPs were familiar with discussing medica-
tion cessation with patients, and were therefore more 
likely to consider short medication trial periods as an op-
tion for patients: 
 ‘I think what some people don’t realise, and I had to spell out 
for one lady, was that they can stop it, because I think people think, 
‘well how long do you have to take it for’ and I say ‘well in the stud-
ies people took it for 5 years, but if you’ve started to take it and 
you’ve hated it, you could stop’…For a lot of people that doesn’t 
really occur to them.’ (P.H., FHCG clinician, female)
 Complexity 
 Incorporating preventive therapy within a busy clinic 
was considered challenging. Some had very limited time 
to achieve their goals for the consultation, and preventive 
therapy was often left until last and discussed if time re-
mained. There was concern that initiating a conversation 
on preventive therapy without sufficient time to answer 
all questions might be harmful to patient care:
 ‘…There’s so much else to get through…that maybe you have 
5 minutes left at the end and you just don’t have time for a really 
in depth discussion about it. You sort of just throw it out there and 
often it’s new information so they don’t really ask any questions 
because they haven’t really had a chance to process it.’ (P.H., FHCG 
clinician, female)
 GPs were concerned about the complexity of manag-
ing patients experiencing side effects. They were some-
times willing to undertake this role, but felt that their op-
tions for supporting women were limited. 
 ‘No. Not comfortable [managing side effects]. Apart from an 
option of stopping the medication, I wouldn’t really know how to 
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manage something. I wouldn’t feel comfortable giving more drugs 
to treat a side effect in that case.’ (Y.T., GP, female)
 FHCG clinicians who were not qualified in medicine 
discussed that they were not trained to take on a manage-
ment role. This highlights an important gap between GPs 
and FHCG clinicians in terms of responsibility for patient 
care:
 ‘…my assumption would be the GP [would manage side ef-
fects], because we can’t take that on, because I’m not a medically 
trained person, so I would have to ask the GP to manage them…
and that’s where I don’t know if they’d be willing to take that on.’ 
(T.D., FHCG clinician, female)
 Costs 
 The financial implications of preventive therapy were 
rarely mentioned by FHCG clinicians. GPs were more 
aware of cost, and those with less experience or who were 
employed on a salary rather than as a practice partner 
were guided by their senior colleagues. Several mentioned 
that they would seek clinical commissioning group (CCG) 
approval, but there was little indication that cost would 
form an insurmountable barrier to prescribing. 
 ‘The funding, in terms of if we prescribe the medication, it 
comes out of our primary care budget. But that wouldn’t concern 
me; I think my concern is to give the best possible care to the pa-
tient and evidence-based treatment which is as safe as possible.’ 
(J.N., GP, Male)
 Outer Setting 
 External Policies 
 The NICE guidelines for the management of familial 
breast cancer were a feature of most interviews with 
FHCG clinicians. They spoke of difficulties interpreting 
the guidelines’ wording, making particular reference to 
the section describing which patient groups were eligible 
for preventive therapy. The use of the word ‘consider’ in 
reference to offering preventive therapy to women at 
moderate risk was thought to be particularly troublesome 
to implementing the guidelines in clinical practice: 
 ‘I think the difficulty has been in implementing this guidance, 
because of the use of this word ‘consider’…having been to some 
national meetings the feeling was, if anything says ‘consider’, 
you’re unlikely to have the resources, and [so] don’t go there. Don’t 
offer it.’ (A.N., FHCG clinician, female)
 The lack of guidance from NICE with regard to who 
should initiate prescriptions and offer subsequent patient 
care led to confusion. While preventive therapy was still 
being discussed with patients, FHCG clinicians were hes-
itant to go into too much detail because prescribing pro-
tocols were uncertain: 
 ‘…Everyone’s caught a bit off guard by the recommenda-
tions…We [clinical genetics] are not willing to take [prescribing] 
on and we can’t, the breast team don’t want to take it on and I sus-
pect the GPs don’t want to either…so you’re almost relieved when 
they say they’re not interested.’ (B.F., FHCG clinician, female)
 Some FHCG clinicians were not medically trained, 
and so could not take on the role of prescribing. Further-
more, even medically trained FHCG clinicians were un-
familiar with prescribing medication and had little expe-
rience in the area. The lack of access to patient records led 
FHCG clinicians to suggest primary care may be the most 
suitable group to initiate prescribing: 
 ‘It’s much better to have it started off with their GP, who can 
check it off with other medications that they might be on…[If] the 
patient doesn’t turn up with that list [of medication]…then you 
can’t really do that due diligence. So that’s another reason for put-
ting it back to the GP.’ (C.S., FHCG clinician, female)
 However, there was a clear reluctance from GPs to 
write the first prescription, and they preferred instead to 
continue it after initiation from secondary or tertiary 
care. One GP provides anecdotal evidence of this reluc-
tance from GPs: 
 ‘One of their [clinical genetics] representatives had come to 
explain how the service was going to be set up and [they] started 
talking about [chemoprevention] as well because she’d suggested 
that GPs would initiate prescriptions. And the whole place was 
roaring with horror.’ (O.C., GP, female)
 Both FHCG clinicians and GPs were concerned about 
prescribing a medication ‘off-label’. Most GPs were un-
aware that tamoxifen and raloxifene were not licensed for 
a primary prevention indication. After being informed, 
GPs willingness to take on the prescribing role was re-
duced because of medico-legal concerns: 
 ‘I think particularly in this day and age, GPs, all doctors are so 
worried about getting sued, that people would be concerned if 
something adverse happened and it came back and it wasn’t li-
censed, that that could be another thing levied at them.’ (D.D., GP, 
female)
 However, GPs discussed their experience of prescrib-
ing other off-label medications, such as for children and 
pregnant women. While they were cautious about pre-
scribing in an off-label context, the status of the licence 
would not prevent them from doing so: 
 ‘I suppose the main issue is obviously with it being off-licence. 
But if it had come from secondary care and I had a letter, discussed 
it with her and discussed that it was off-licensed, I feel happy that 
the responsibility is kind of a, you know, they’ve taken the prima-
ry decision, and we are supporting it by prescribing.’ (D.D., GP, 
female)
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 Inner Setting 
 Implementation Climate 
 Several FHCG clinicians reported that their clinic was 
not enthusiastic about implementing preventive therapy 
within their service. In clinics with affected and unaffect-
ed patients, the priority was on treating patients with can-
cer rather than prevention in high risk groups:
 ‘They’re [senior colleagues] so involved with dealing with can-
cer patients, and discharging patients who don’t have cancer back 
to their GPs, this chemoprevention is not on their agenda.’ (R.P., 
FHCG clinician, male)
 In some centres, a lack of awareness about preventive 
therapy among senior clinicians was considered to inhib-
it implementation across the whole service. In other cen-
tres, senior clinicians were perceived to be making as-
sumptions about the knowledge of less experienced staff 
members: 
 ‘I think there are people that have been involved in these stud-
ies, and they have a certain level of knowledge and just expect ev-
erybody else to know what they know, which is not possible if you 
haven’t been involved.’ (T.D., FHCG clinician, female)
 Individuals Involved 
 Knowledge, Attitudes and Self-Efficacy 
 Some FHCG staff felt they were not sufficiently knowl-
edgeable to be discussing preventive therapy with patients 
and lacked confidence in their own understanding. There 
was also uncertainty with regard to the evidence for SERMs 
among carriers of deleterious BRCA gene mutations. Some 
FHCG clinicians were unaware of the better cost/benefit 
ratio among BRCA 2 carriers relative to BRCA 1 carriers: 
 ‘It’s difficult because of the actual lack of research, but what 
[are] the actual statistical benefits for different groups of patients. 
If they’re BRCA 1, BRCA 2, are they the same?’ (L.O., FHCG clini-
cian, female)
 GPs were broadly familiar with some side effects of 
tamoxifen, but rarely listed thromboembolic events or 
endometrial cancer. FHCG clinicians were more aware, 
although gaps in knowledge were apparent. For example, 
one FHCG clinician was unwilling to prescribe tamoxifen 
because they wanted all patients to undergo bone density 
scans prior to initiating therapy. This is despite bone den-
sity only decreasing in pre-menopausal women  [25] and 
fracture rates improving overall among women using 
SERMs  [4] :
 ‘If I was the person prescribing it…I’d want to perhaps have a 
bone density scan and consideration of that person’s bone health 
because we will cause the bone density to drop, and in a healthy 
person that’s a risk that I don’t think is fully worked out yet.’ (C.S., 
FHCG clinician, female)
 Throughout all discussions of preventive therapy, ral-
oxifene was rarely mentioned. Clinicians reported know-
ing very little about this drug: 
 ‘I haven’t come across using raloxifene at all… So basically che-
moprevention for me is tamoxifen.’ (T.T., FHCG clinician, female)
 Discussion 
 In this qualitative investigation, GPs and clinicians 
working in a familial breast cancer setting reported mul-
tiple barriers to the implementation of preventive therapy 
within routine clinical practice. Difficulties across a range 
of CFIR domains were reported, with FHCG clinicians 
describing particular problems with interpreting NICE 
guidelines and agreeing protocols for prescribing. While 
most clinicians were interested in the concept of preven-
tive therapy, the relative benefit for patients was consid-
ered to be small. Clinicians from both groups reported 
knowing relatively little about the topic, which discour-
aged discussions with patients, and this may be affecting 
uptake by women. 
 This study has implications for the care of women at 
higher risk of familial breast cancer. Some FHCG clini-
cians felt poorly informed about the evidence for preven-
tive therapy, particularly with reference to specific clini-
cal groups. Similar findings were observed among Aus-
tralian clinicians who reported a preference for discussing 
preventive therapy with carriers of BRCA1 and BRCA2 
deleterious mutations, despite a lack of evidence in these 
groups  [11] . Encouraging dissemination of clinical trial 
findings through study days and local network meetings 
could improve clinician knowledge and enhance the 
quality of communication with patients. Such events 
should be carefully developed and informed by the barri-
ers identified in the CFIR framework here. 
 For example, future research is needed to develop an 
evidence-based educational event addressing CFIR barri-
ers such as knowledge of preventive medications, aware-
ness of drug harms and benefits, and use of national 
guidelines. Such a strategy may reduce clinician’s reluc-
tance to initiate discussions about preventive therapy and 
enhance women’s ability to make an informed decision 
 [26, 27] . Knowledge deficits were noted with GPs, who 
were mostly unaware that tamoxifen and raloxifene could 
be used for primary prevention. GPs were reluctant to 
take on the role of managing women using preventive 
therapy because they felt their knowledge was insuffi-
cient. Several strategies for improving GP knowledge 
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were suggested, including using websites and publica-
tions to disseminate up-to-date scientific advice on the 
topic. They also suggested developing a brief pro forma 
on preventive therapy for secondary and tertiary care cli-
nicians to include when asking GPs to prescribe. We plan 
to create template pro formas for FHCG clinicians to use 
and adapt. These will address many of the barriers identi-
fied from the CFIR framework, and the development pro-
cess will involve GP stakeholders. A further benefit of 
providing these templates is that it will ensure the infor-
mation provided to clinicians and patients is standardised 
across different regions.
 Time was a barrier to discussing preventive therapy 
within clinics. FHCG clinicians were understandably re-
luctant to introduce a new topic to a consultation that was 
already short and complex. Decision aids have been eval-
uated in trial and clinical settings  [28–33] , and can im-
prove patient decision-making in the absence of a clini-
cian  [34] . However, FHCG clinicians would be needed to 
follow-up with patients to ensure women have been able 
to make an informed decision. The financial implications 
of this need to be carefully monitored, and it may not be 
possible for all centres. Identifying cost-effective solu-
tions to inform patients about preventive therapy in a 
simple format should be a priority for research and clini-
cal practice.
 Side effects are a major deterrent to initiating preven-
tive therapy  [35, 36] , but few FHCG clinicians raised the 
topic of offering patients a short trial to assess their toler-
ance. GPs were more likely to suggest this possibility. 
FHCG clinicians should be encouraged to explain to pa-
tients that they are not expected to persist with therapy if 
they are unable to tolerate side effects. Short medication 
trials have the potential to improve informed decision-
making by allowing their initial response to be taken into 
consideration when choosing whether to persist with pre-
ventive therapy.
 This study also has implications for policy, particularly 
with regard to the NICE guidelines for the management 
of familial breast cancer, which uses the term ‘consider’ 
when describing which patient groups should be offered 
preventive therapy  [7] . Our findings showed ‘consider’ 
was being interpreted by FHCG clinicians as something 
that should not be done in clinic, and should therefore be 
revised or clarified in the next version of the guideline. 
The lack of guidance for prescribing also appears to be 
hampering efforts to implement preventive therapy. A 
‘one size fits all’ approach is unlikely to be possible, and 
our data highlight several issues that warrant consider-
ation when developing local protocols. Opening commu-
nication channels between the two groups and involving 
all stakeholders will be key to resolving these problems. 
Future NICE guidance could offer several prescribing sce-
narios to facilitate the development of local protocols.
 The majority of comments were accommodated with-
in the five domains of the CFIR model. However, discus-
sion regarding process was more closely aligned with oth-
er domains, such as the influence of policy in the outer 
setting. This adaption was in keeping with the original 
framework, which was not intended to be a finalised 
model for implementation research  [18] . Our data are 
also similar to a study using the CFIR to investigate bar-
riers to prescribing biologic medication to treat rheuma-
toid arthritis  [20] . Further investigations are needed in 
other contexts, but convincing clinicians of the effective-
ness of the medication and ensuring there is clear guid-
ance for prescribing appears to be important when intro-
ducing new medical therapies in clinical practice. Future 
trials to promote the implementation of guidelines are 
needed, and our data suggest that the CFIR model is a 
useful model on which to base these strategies.
 This study had limitations. Our qualitative approach 
prohibited us from reporting the proportion of clinicians 
who experienced the barriers or the magnitude of their 
importance. The majority of the clinicians involved were 
female, and it is possible that gender influenced attitudes 
towards preventive therapy. We also relied on opportu-
nistic recruitment, and it is not clear whether our findings 
generalise to centres not involved in this research. It is 
possible that clinicians interested in participating in this 
study were more likely to have experienced barriers to 
implementing preventive therapy. Alternatively, they 
could have been more positive about the topic than other 
FHCG clinicians, and our report could be underestimat-
ing the number of implementation barriers.
 Conclusions 
 In conclusion, our qualitative investigation with GPs 
and FHCG clinicians identified multiple barriers to imple-
menting preventive therapy within clinical practice. Clini-
cians reported particular difficulties with interpreting 
NICE guidelines and establishing local protocols for pre-
scribing therapy. Self-reported knowledge of tamoxifen 
and raloxifene was often low, and clinicians felt this de-
tracted from their willingness to discuss preventive therapy 
with patients. The barriers identified in our research can 
be addressed by engaging all of the key stakeholders during 
the development of local and national policy documents.
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